

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7341282

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DAVID CAMPBELL	09/09/2019
JUSTIN CHAPMAN	09/09/2019
MUI CHEUNG	10/03/2019
THOMAS R. DIRAIMONDO	09/09/2019
SERGIO G. DURON	09/09/2019
RECEIVING PARTY DATA	
Name:	SITARI PHARMA, INC.
Street Address:	11099 N. TORREY PINES ROAD,
Internal Address:	SUITE 290
City:	LA JOLLA,
State/Country:	CALIFORNIA
Postal Code:	92037
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17749335
CORRESPONDENCE DATA	
Fax Number:	(610)917-6934
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6109177817
Email:	US_cipkop@gsk.com
Correspondent Name:	GLAXOSMITHKLINE GLOBAL PATENTS UP4110
Address Line 1:	1250 SOUTH COLLEGEVILLE ROAD
Address Line 4:	COLLEGEVILLE, UNITED STATES 19426
ATTORNEY DOCKET NUMBER:	PU66786C1
NAME OF SUBMITTER:	SANDRA MANTON
SIGNATURE:	/SANDRA MANTON/
DATE SIGNED:	05/20/2022
Total Attachments: 4	

source=PU66786C1_US_Assignment_from_Parent#page1.tif

source=PU66786C1_US_Assignment_from_Parent#page2.tif

source=PU66786C1_US_Assignment_from_Parent#page3.tif

source=PU66786C1_US_Assignment_from_Parent#page4.tif

PATENT

REEL: 059968 FRAME: 0680

Assignment

WHEREAS I/WE, **David CAMPBELL** of La Jolla, California USA, a citizen of the United States of America; **Justin CHAPMAN** of La Jolla, California USA, a citizen of the United States of America; **Mui H. CHEUNG** of Collegeville, Pennsylvania USA, a citizen of the United States of America; **Thomas R. DIRAIMONDO** of La Jolla, California USA, a citizen of the United States of America and **Sergio G. DURON** of La Jolla, California USA, a citizen of the United States of America; (hereinafter called "the inventor(s)") have invented or discovered certain improvements in "TRANSGLUTAMINASE 2 (TG2) INHIBITORS" (hereinafter referred to as "the invention and improvements") for which priority application '62/717697 was filed on **10-Aug-2018** and **62/845229** was filed on **8 May 2019** in the United States, and for which a PCT international application **PCT/US2019/045827** was filed on **09-Aug-2019**, designating the United States of America.

WHEREAS, **SITARI PHARMA, INC.**, a company incorporated in the State of Delaware, USA, having an address at **11099 N. Torrey Pines Road, Suite 290 La Jolla, California 92037 United States of America**, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements and any Letters Patent to be obtained therefor, in all countries, including the United States, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, **David CAMPBELL, Justin CHAPMAN, Mui CHEUNG, Thomas R. DIRAIMONDO and Sergio G. DURON** for good and valuable consideration unto me/us moving, the receipt whereof is hereby acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and transfer my/our whole right, title and interest in and to said invention and improvements to said **SITARI PHARMA, INC.**, throughout the United States of America, its territories and possessions, and in and to said application and any extensions, reissues, continuations, continuations-in-part, and any divisions thereof, and in and to any and all Letters Patent of the United States of America,






AND, my/our whole right, title and interest in and to said invention and improvements to **SITARI PHARMA, INC.**, in all other countries throughout the world, and in and to any applications in said other countries, and continuations-in-part, patents of addition, revalidation patents, patents of importation, registrations, and any renewals, extensions and divisions thereof, and in and to any and all Letters Patent of said all other countries which may be granted on said invention and improvements including any priority rights under the International Convention

AND, I/we do hereby authorize and request the issue of any Letters Patent in the respective areas referred to, to said **SITARI PHARMA, INC.**, as assignees of my/our whole right, title and interest in and to the same for the sole use and behalf of the said assignees, their successors and assigns as their interests appear herein,

AND, I/we warrant that I/we have not knowingly conveyed to others any right in said invention, improvements, applications or patents or any license to use the same or to make, use or sell anything embodying or utilizing said invention and improvements and that I/we have good right to assign the same to **SITARI PHARMA, INC.**;

AND, I/we the undersigned **David CAMPBELL, Justin CHAPMAN, Mui CHEUNG, Thomas R. DIRAIMONDO and Sergio G. DURON** all representatives, will provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, application papers, affidavits, assignments and other documents which may be necessary or desirable to more effectually secure to and vest in said **SITARI PHARMA, INC.**, their successors and assigns, the whole right, title and interest in and to the said invention and improvements, applications, Letters Patent, rights, title and interest hereby sold, assigned and conveyed, or intended so to be.

IN WITNESS whereof and with effect from the **10-Aug-2018**, the inventor(s) and the Attorney & Authorised Official of **SITARI PHARMA, INC.** have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.

Inventor Name	Signature	Date
 David CAMPBELL		Date: <u>09.08.19</u>
 Justin CHAPMAN		Date: <u>9/09/2019</u>
 Mui CHEUNG		Date: <u> </u>
 Thomas R. DIRAIMONDO		Date: <u>9/9/19</u>
 Sergio G. DURON		Date: <u>9/9/19</u>

SIGNED by Jay Lichter As the
Authorised Official of **SITARI PHARMA, INC.**


Signature

Date. 9/9/2019

ASSIGNMENT

WHEREAS I/WE, **Mui CHEUNG** of Collegeville, Pennsylvania USA, a citizen of the United States of America; (hereinafter called "the inventor(s)") have invented or discovered certain improvements in **"TRANSGLUTAMINASE 2 (TG2) INHIBITORS"** (hereinafter referred to as "the invention and improvements") for which priority application **62/717697** was filed on **10-Aug-2018** and **62/845229** was filed on **8 May 2019** in the United States, and for which a PCT international application **PCT/US2019/045827** was filed on **09-Aug-2019**, designating the United States of America.

WHEREAS, **GLAXOSMITHKLINE LLC**, a company incorporated in the State of Delaware, USA, whose registered address is **251 Little Falls Drive, Wilmington, Delaware 19808, United States of America**, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements, including the right to claim priority, and in and to and any Letters Patent to be obtained therefor, in all countries, including the United States, its territories and possessions, and

WHEREAS **SITARI PHARMA, INC.**, a company incorporated in the State of Delaware, USA, having an address at **11099 N. Torrey Pines Road, Suite 290 La Jolla, California 92037 United States of America**, is desirous of acquiring from **GLAXOSMITHKLINE LLC** the whole right, title and interest in and to the invention and improvements and in and to any applications for the invention and improvements and any Letters Patent to be obtained therefor, in all countries, including the United States of America, its territories and possessions;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXOSMITHKLINE LLC** of the invention and improvements and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in and to the invention and improvements and the application, (which I/we do not believe to be the case and claim no ownership right, title or interest in and to the invention and improvements and to the application based on the law of the United States), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and improvements and to the application, including the right to claim priority from the application in respect of any subsequent applications, to **GLAXOSMITHKLINE LLC**. **GLAXOSMITHKLINE LLC** hereby assigns and transfers to **SITARI PHARMA, INC** its whole right, title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and improvements and in and to the application including the right to claim priority from the application in

respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof, and I/we the inventor(s) and GLAXOSMITHKLINE LLC hereby authorise and request any patent arising therefrom, in all countries, including the United States of America, its territories and possessions, be issued to SITARI PHARMA, INC;


AND GLAXOSMITHKLINE LLC hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree at the request and cost of SITARI PHARMA, INC to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in SITARI PHARMA, INC its successors and assigns, the whole right, title and interest in and to the invention and improvements and in and to the application hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.

IN WITNESS whereof and with effect from the **10 August 2018**, the inventor(s) and the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and SITARI PHARMA, INC have hereunto set their respective hands.


 _____ Date: 3 Oct 2019
Mui CHEUNG

SIGNED by Duke M. Fitch

As the Attorney & Authorised Official of GLAXOSMITHKLINE LLC


 _____ Date: 3 OCT 2019

SIGNED by Jay Lichter

As the CEO of SITARI PHARMA, INC


 _____ Date: 10/04/2019